System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Dominique Penther is an expert in Hematology at Centre Henri Becquerel (France). Dominique Penther has authored 112 publications, the most recent in 2026, and is an investigator in 2 clinical trials, 1 of them ongoing. SLR score: 264 (community average: 125). How the SLR is computed.

LeadR Profile

Dominique Penther Centre Henri Becquerel France
264 ScienceLeadR Reputation 264

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2009 - 2026
Source: PubMed

Centre Henri Becquerel

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 112

Citations

Citations: 1 890 1st author: 3 Last author: 4 Unique author: 0

Main journals

Blood 20
Leukemia 17
Genes Chromosomes Cancer 9
Br J Haematol 7
Leuk Res 7

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Prognostic Impact of FLT3-ITD Allelic Ratio in AML Patients Treated With High-Dose Anthracycline and a FLT3 Inhibitor.
PMID 42934825 — disease-free survival, hematology, anthracyclines		Am J Hematol20260
Potential Benefit of Ruxolitinib in Suspected Ocular and Neurological Transplant-Associated Thrombotic Microangiopathy After Allogeneic Stem Cell Transplantation: A Case Report and Review.
PMID 42819691 — thrombotic microangiopathies, cells, microscopy, electron, scanning transmission, stem cells, transplants, cell transplantation, stem cell transplantation, transplantation		Clin Case Rep20260
PD-L2 is associated with lineage-related transcriptional programs distinct from PD-L1 in primary mediastinal large B-cell lymphoma.
PMID 42386908 — cells, lymphoma, b-cell, lymphoma, leukemia, ligands, b-lymphocytes		Leukemia20260
Genomic landscape of acute myeloid leukemia in adolescents and young adults.
PMID 42350606 — leukemia, leukemia, myeloid, acute, adolescent, leukemia, myeloid		Leukemia20260
Prognostic impact of intensive chemotherapy in patients with TP53-mutated AML.
PMID 42336836 — drug therapy, chemotherapy		Blood Cancer J20260

Clinical Studies 2

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 2 1
Phase 2/Phase 3 1

By status:

Active not recruiting 1
Recruiting 1

By type:

Interventional 2

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 0
multicentricup10 2

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide Doxorubicin Vincristine and Prednisone (CHOP) in Circulating Tumor (ct)DNA High Risk Patients With Untreated Diffuse Large B Cell Lymphoma
NCT04980222 — cytokines, cells, body surface area, prednisolone, safety, prednisone, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, cyclophosphamide, doxorubicin, neoplasms, cytokine release syndrome, rituximab, vincristine, therapeutics, b-lymphocytes		Phase 2Active not recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS